IHC Assays for Companion Diagnostic Use: Standardization Methods That Maximize Success a New and Upcoming Webinar Hosted by Xtalks
Toronto, Canada (PRWEB) February 25, 2014 -- Today, IHC assay tests are commonly designed with limited stringency in comparison to common ELISA tests in the clinical setting. IHC scoring and cutpoints are determined arbitrarily biased toward the performance of the assay and then compared to patient response in hopes of finding a predictive biomarker.
In this webinar, Sharon Moulis, Principal Scientist and Director of Human Tissues Laboratory at Merrimack Pharmaceuticals, will discuss how they have devised a method of IHC assay design that increases the chance of finding the optimal cutpoint of biomarker expression and maximizing the chance of success for companion diagnostic use. Through use of standard curves and quantitative image analysis, the required target expression level can be determined and IHC assays re-optimized for more uniform and consistent scoring by a pathologist.
For more information on this webinar or to register, visit IHC Assays for Companion Diagnostic Use: Standardization Methods that Maximize Success
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com.
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx.
Contact:
Michelle Tran
Tel: +1 (416) 977-6555 ext 224
Email: mtran(at)xtalks(dot)com
Client Services, Xtalks, +1 (416) 977-6555 Ext: 227, [email protected]
Share this article